Literature DB >> 15316743

The relationship between vascular and metabolic characteristics of primary breast tumours.

Scott I K Semple1, Fiona J Gilbert, Thomas W Redpath, Roger T Staff, Trevor S Ahearn, Andrew E Welch, Steven D Heys, Andrew W Hutcheon, Elizabeth H Smyth, Shailesh Chaturvedi.   

Abstract

The objective of this study was to investigate the relationship between vascular and metabolic characteristics of breast tumours in vivo, using contrast-enhanced dynamic MRI and 2-[(18)F] fluoro-2-deoxy- d-glucose (FDG) PET imaging. Twenty patients with large or locally advanced primary breast cancers were imaged prior to therapy. MRI data were acquired using a dynamic gradient echo sequence and analysed using two pharmacokinetic models. Static PET data were acquired in 2D mode. A significant association ( P<0.05) was observed between the calculated exchange rate constants of both pharmacokinetic models and calculated PET FDG dose uptake ratios (DUR). Statistical analysis showed that the exchange rate constants can explain between 27 and 44% of the variance observed in the PET FDG uptake ratios. A relationship was demonstrated between the vascular and metabolic characteristics of primary breast tumours showing that any assessment of tumour metabolic activity using PET may be controlled at least in part by delivery of uptake agent due to the vascular characteristics of the tumour. MRI and PET provide methods of assessing breast tumour vascularity and metabolism in vivo using the exchange rate constants of dynamic MRI, and DUR of PET, respectively, these measures being related but not equivalent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316743     DOI: 10.1007/s00330-004-2454-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  28 in total

Review 1.  Nuclear medicine techniques for the study of breast cancer.

Authors:  E Bombardieri; F Crippa; L Maffioli; M Greco
Journal:  Eur J Nucl Med       Date:  1997-07

2.  Glucose transport and phosphorylation in skeletal muscle in obesity: insight from a muscle-specific positron emission tomography model.

Authors:  Katherine V Williams; Alessandra Bertoldo; Bruno Mattioni; Julie C Price; Claudio Cobelli; David E Kelley
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

Review 3.  MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy.

Authors:  M V Knopp; G Brix; H J Junkermann; H P Sinn
Journal:  Magn Reson Imaging Clin N Am       Date:  1994-11       Impact factor: 2.266

4.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

5.  Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience.

Authors:  G Brix; M Henze; M V Knopp; R Lucht; J Doll; H Junkermann; H Hawighorst; U Haberkorn
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

6.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

7.  Standardized uptake values of FDG: body surface area correction is preferable to body weight correction.

Authors:  C K Kim; N C Gupta; B Chandramouli; A Alavi
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

8.  Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI.

Authors:  F W Flickinger; J D Allison; R M Sherry; J C Wright
Journal:  Magn Reson Imaging       Date:  1993       Impact factor: 2.546

9.  Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model.

Authors:  P S Tofts; B Berkowitz; M D Schnall
Journal:  Magn Reson Med       Date:  1995-04       Impact factor: 4.668

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

View more
  18 in total

1.  Investigating tumor perfusion and metabolism using multiple hyperpolarized (13)C compounds: HP001, pyruvate and urea.

Authors:  Cornelius von Morze; Peder E Z Larson; Simon Hu; Hikari A I Yoshihara; Robert A Bok; Andrei Goga; Jan Henrik Ardenkjaer-Larsen; Daniel B Vigneron
Journal:  Magn Reson Imaging       Date:  2011-12-12       Impact factor: 2.546

Review 2.  Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts.

Authors:  Hee Kang; Ho Yun Lee; Kyung Soo Lee; Jae-Hun Kim
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

3.  Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Savannah C Partridge; Risa K Vanantwerp; Robert K Doot; Xiaoyu Chai; Brenda F Kurland; Peter R Eby; Jennifer M Specht; Lisa K Dunnwald; Erin K Schubert; Constance D Lehman; David A Mankoff
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

Review 4.  Hybrid PET-dynamic CECT in the management of breast cancer.

Authors:  Rakesh Kumar; Chandan Jyoti Das
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

5.  Pretreatment PET in breast cancer: is there a role?

Authors:  Sue Chua; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 9.236

6.  An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer.

Authors:  Sotirios Bisdas; Oliver Seitz; Markus Middendorp; Nicole Chambron-Pinho; Theodosios Bisdas; Thomas J Vogl; Renate Hammerstingl; Ulrike Ernemann; Martin G Mack
Journal:  Eur Radiol       Date:  2010-05-05       Impact factor: 5.315

7.  Comparison of diffuse optical tomography of human breast with whole-body and breast-only positron emission tomography.

Authors:  Soren D Konecky; Regine Choe; Alper Corlu; Kijoon Lee; Rony Wiener; Shyam M Srinivas; Janet R Saffer; Richard Freifelder; Joel S Karp; Nassim Hajjioui; Fred Azar; Arjun G Yodh
Journal:  Med Phys       Date:  2008-02       Impact factor: 4.071

8.  Blood flow-metabolism mismatch: good for the tumor, bad for the patient.

Authors:  David A Mankoff; Lisa K Dunnwald; Savannah C Partridge; Jennifer M Specht
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

9.  Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Robert B Livingston; Hannah M Linden; Jennifer M Specht; Robert K Doot; Thomas J Lawton; William E Barlow; Brenda F Kurland; Erin K Schubert; David A Mankoff
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

10.  Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Authors:  Marjan S Bolouri; Sjoerd G Elias; Dorota J Wisner; Spencer C Behr; Randall A Hawkins; Sachiko A Suzuki; Krysta S Banfield; Bonnie N Joe; Nola M Hylton
Journal:  Radiology       Date:  2013-07-22       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.